Xeris at H.C. Wainwright conference: growth engine widens

On Monday, September 14, 2026, Xeris Pharmaceuticals (XERS) spoke at the H.C. Wainwright 28th Annual Global Investment Conference to discuss the company's continued rapid growth and a new pipeline asset that could expand its market reach. Management highlighted strong revenue increases and high profit margins, while acknowledging that future success depends on successful clinical trials, regulatory approval, and insurer acceptance.

The company anticipates at least 33% revenue growth this year, following growth rates of 40% to 50% in the previous year. Gross margins are approximately 85% and continue to improve, providing financial flexibility for both sales expansion and further development.

RECORLEV remains the primary growth driver, projected to reach $1 billion in revenue by 2030. Xeris recently introduced XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, as an innovative long-term opportunity. The company believes it can fund XP-8121 development internally, without external financing. Xeris emphasized its robust commercial business and self-sustaining cash flow generation to support both existing products and new developments.

The company projected total company revenue of $750 million by 2030, with RECORLEV alone expected to reach $1 billion in revenue during the same period. CEO John Shannon affirmed that all three core products—GVOKE, KEVEYIS, and RECORLEV—are experiencing growth, with RECORLEV driving most of the company's expansion. Xeris has successfully doubled its commercial base, including field sales, patient reimbursement, and pharmacy services, and now reaches nearly every endocrinologist.

The market for Cushing's syndrome is growing faster than anticipated, and Xeris has been able to keep pace with this demand. Management doubled the commercial infrastructure earlier in the year to support the company's expanding presence in the endocrinology space.